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INTRODUCTION 
Diabetes mellitus, often assigned to as diabetes, comes under the group 
of metabolic diseases characterized by high blood sugar levels over a prolonged 
period due to alteration in either the insulin secretion, insulin action, or both.   
Worldwide, as of the recent 2016 data collected from the World Health 
Organization (WHO) around 422 million adults have diabetes mellitus which is 
proposed/estimated to almost double by 2030 which is composed of mainly type 2 
diabetes (85-90% of all cases).
[1] 
The statistics compiled from the World Health Organization (WHO) in 2012 
reports about/around 1.5 million deaths worldwide assigning it as the eighth 
leading cause of death which has increased to around 4.9 million deaths in 2014 as 
estimated by the International Diabetes Federation (IDF). 
Diabetic foot, characterized by ischemia, peripheral neuropathy, 
osteoarthropathy, foot ulcer and infections possesses a major burden both to the 
community and to the patient. 
With a prevalence of 65.1 million, India holds the second place in the world. 
In India, around 2.4% of the rural and 12-17% of the urban population have 
diabetes. The lifetime risk of developing foot ulcers in diabetes is estimated to be 
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around 15-20%. The amputation rates can be cut down to 49-85% by a 
multidisciplinary approach. 
Management of chronic diabetic foot ulcers is demanding and requires a 
multidisciplinary approach. Even though many techniques have been advocated, 
there is no particular substantiation to prove a type of dressing better than the 
other. 
[2]
  
With the latest approaches/advances in the theory, factors and cell types of 
wound healing, a new pathway has been initiated in the treatment of chronic 
diabetic foot ulcers. Recombinant Human Epidermal Growth Factor (rhEGF) is 
one amidst the various growth factors which acts as a mitogen and aids in cellular 
proliferation, differentiation and migration. 
The present study was conducted to analyse the adequacy/effectiveness of 
topical Recombinant Human Epidermal Growth Factor (rhEGF) in the healing of 
diabetic wounds as against the conventional EUSOL (Edinburgh University 
Solution Of Lime) dressing. rhEGF cuts down the duration needed for wound 
healing and the mean closure was notably higher in the rhEGF group. 
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OBJECTIVES OF THE STUDY 
To compare the efficacy of topical Recombinant Human Epidermal Growth Factor 
(rhEGF) versus EUSOL (Edinburgh University Solution Of Lime) dressing in the 
healing of diabetic wounds in terms of: 
 Duration required for wound healing. 
 Rate of granulation tissue formation as percentage of the total surface area 
 Rate of reduction in mean ulcer surface area. 
 Any cellulitis in the surrounding area. 
Primarily aiding in complete healing of the ulcer. 
Secondarily resulting in the reduction of the surface area of the wound to get 
closed by suturing/skin graft/flap cover. 
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REVIEW OF LITERATURE 
HISTORY OF DIABETES MELLITUS: 
Ebers Papyrus from 1500 BCE portrayed/interpreted diabetes as “too great 
emptying of the urine”.[3] On the other hand, just because the urine from people 
suffering from diabetes attracted ants, physicians in India ascribed diabetes 
as “madhumeha” .During 400-500 CE, Sushruta and Charaka interpreted type 1 
diabetes mellitus and type 2 diabetes mellitus as separate conditions and the 
distinction made by Sir Harold Percival (Harry) Himsworth was published in 
1936.
[4] 
Ancient Greek physician Aretaeus of Cappadocia illustrated the increased 
quantity of urine excreting through the kidneys and gave the first outright 
explanation of diabetes.
 
Sir Edward Albert Sharpey-Schafer noted an insufficiency in a single 
chemical produced by the pancreas which he preferred calling it 'Insulin'. 
Sir Frederick Grant Banting and Charles Herbert Best reversed the effect of 
induced diabetes in dogs by injecting an extract of the islets of Langerhans from 
the pancreas of healthy dog which led to the discovery of insulin.
 
On January 23, 
1922, the extract was injected to a 14 year old boy suffering from diabetes and an 
improvement in his clinical condition and reduction of blood sugar levels was 
noted.  
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Sir Frederick Grant Banting  is privileged by World Diabetes Day which is 
held on his birthday i.e., November 14 every year. In 1983 the first human insulin 
was invented. 
HISTORICAL ASPECTS OF DIABETIC FOOT: 
In the pre-insulin era, Frank N.Allan described the major complication of 
diabetes, the diabetic foot ulcer. Due to the momentousness of diabetic foot in the 
second half of the 20
th
 century, clinicians investigated it even though it was 
recognized as early as the 19
th
 century. 
 
Oakley and Dupless indexed the aetiological factors involved in diabetic 
foot in 1956 and 1970 respectively. Based on the Laing, Patrick et al published in 
1998, peripheral neuropathy, osteoarthropathy and ischaemia were culpable for 
foot ulcer in diabetes. 
[5] 
Worldwide, diabetes leads to the loss of a lower limb every 20 seconds. 
[6] 
Five-year recurrence rates of diabetic foot ulcers are as high as 70%. 
EUSOL (Edinburgh University Solution Of Lime): 
It was introduced by Smith during the wartime which separates the slough 
from the ulcer bed by releasing nascent chlorine and aids in wound healing.
 [12] 
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RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR:
 
Abundant trials have been executed over the last decade to study the potency 
of epidermal growth factors since its invention by Cohen in 1962 which acts by 
triggering cellular growth, differentiation and proliferation in the healing of 
diabetic foot ulcers. Based on a pilot study conducted using 28 diabetic patients 
with foot ulcer, the drug was tolerated well and positive response was obtained in 
the healing of wounds. 
[7]
 It is authorized for the treatment of diabetic foot ulcers 
and appears appropriate when compared with the conventional dressings in the 
management of diabetic foot ulcer. 
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HISTORICAL ASPECTS OF WOUND HEALING 
According to the primeval medical article described on a clay tablet in 2200 
BC, there are „three healing gestures‟ – washing the wounds, making the plasters in 
which oil was the primary ingredient both in terms of preventing infection and as a 
non-adherent dressing and bandaging the wound which was described by the 
Egyptians and honey, grease, oiled frog skins and lint were used. Skin grafts were 
advocated as early as 700 BC. 
 
Occlusive dressings which are efficient in keeping a 
moist environment were originally described by the Sumerians. 
Egyptians used to paint wounds with green colour which consists of copper 
that is noxious to the bacteria and which aids in preventing infection. It was the 
Greeks who discriminated fresh or acute, chronic and non - healing wounds. An 
excellent quotation by Hippocrates on wound healing is, “For an obstinate ulcer, 
sweet wine and a lot of patience should be enough”. 
The infection rates are likely to be higher in all war wounds and hence 
should be debrided was Antoine Depage‟s philosophy who was a Belgian surgeon. 
Gamgee introduced his first dressing in the form of degreased cotton 
wrapped in bleached lint which absorbs fluids in the 19
th
 century. Cotton gauze 
impregnated with liquid paraffin was used to prevent the dressing from sticking to 
the wound and this was introduced by Lumiere in France. 
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Management of the chronic wound has taken a new turn over the past two 
decades due to: 
 The vast research in wound healing. 
 Importance on the social and financial impacts by the governmental 
agencies. 
 Evolution of new pharmacological agents. 
 Advent of better reconstructive surgical techniques. 
 Mechanisms involved in repair of the wound are classified at 3 levels 
namely the anatomic, molecular and biochemical level. 
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SURGICAL ANATOMY OF THE FOOT 
 A clear perception of the anatomy of the foot is essential for the prevention 
of diabetic foot infections. The foot contains 26 bones and the function of the foot 
is controlled by 19 intrinsic muscles and 7 extrinsic muscles. The intrinsic muscles 
have their origin and insertion in the foot whereas the extrinsic muscles have their 
origin in the leg and insertion in the foot. 
SOLE OF THE FOOT: 
 The skin on the plantar aspect which is devoid of hair follicles and 
sebaceous glands is about 4mm thick. The weight bearing areas which includes the 
heel, lateral margin of the sole and the areas across the metatarsal heads show fat 
concentrations in the subcutaneous layer. The skin on the sole of the foot is fixed 
and can glide for upto 1cm or less due to the presence of fibrous septa which 
connects the skin and the plantar aponeurosis. 
 The skin on the dorsal aspect is around 2mm thick and can glide upto 2-3cm. 
It is composed of the hair follicles and the scanty sebaceous glands. 
 A defect in the sole of the foot is best treated with a local flap as distant flap 
contains fat devoid of fibrous septa and causes excessive movement of the skin. 
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ARCHES OF THE FOOT: 
 An elastic structure comprising of little bones which are held together by 
ligaments, plantar aponeurosis, tendons and the extrinsic and intrinsic muscles 
constitutes the longitudinal and transverse arches. 
 The foot will appear flat if not supported by the muscles. 
[8] 
PLANTAR APONEUROSIS: 
 The plantar aponeurosis is thickest in the central aspect where it is attached 
to the medial tubercle of the calcaneum and spreads out like a fan. It helps in the 
maintenance of the longitudinal arch. The medial and the lateral aspects of the 
plantar fascia encloses the abductor halluces medially and the abductor digiti 
minimi laterally.  
FOUR LAYERS OF MUSCLES OF THE FOOT: 
FIRST LAYER - abductor halluces and abductor digiti minimi, flexor digitorum 
brevis. 
SECOND LAYER – flexor digitorum, lumbrical muscles. 
THIRD LAYER – flexor hallucis brevis, adductor hallucis, flexor digiti minimi. 
FOURTH LAYER – dorsal and the plantar interossei muscles. 
11 
 
LIGAMENTS IN THE FOOT: 
 Plantar calcaneonavicular or the spring ligament. 
 The long and the short plantar ligaments. 
 Tranverse metatarsal ligament. 
 Interosseus ligaments. 
CAUTIONS TAKEN DURING MANAGEMENT OF FOOT INFECTIONS: 
1. Avoid damaging the nail plate and the digital vessels. 
2. The continuity of the dorsalis pedis has to be maintained as it may act as an 
outflow conduit in bypass procedures. 
3. Unstable ankle may be produced by inadvertently damaging the flexor 
retinaculum which extends between the medial malleolus and the 
calcaneum. 
4. Preserve the malleolar vessels when performing a Syme‟s amputation. 
5. Collapse of the arches can result from the division of tibialis posterior and 
peroneus longus tendon. 
6. Therapeutic footwear are designed based on the knowledge of the anatomy 
of the tarsal and the metatarsal joints. 
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7. A proper understanding of the surface anatomy of the nerves is important 
which aids in regional block anaesthesia while performing surgeries in the 
distal foot. 
 
WOUND HEALING 
The entire mechanism of wound healing is complicated and is aimed to 
bring about anatomical and functional integrity of disrupted tissue and is liable to 
break down culminating in the evolution of chronic non-healing wounds. 
TYPES OF WOUND HEALING: 
[9] 
TERMS USED 
IN WOUND 
HEALING 
PRIMARY 
INTENTION 
SECONDARY 
INTENTION 
TERTIARY 
INTENTION 
 Refers to the 
healing of clean 
wound with little 
interruption to the 
local tissue and 
epithelial basement 
membrane by 
suturing or other 
methods 
Wounds with 
significant tissue 
loss is allowed to 
granulate by 
packing with gauze 
and applying a 
dressing 
Checked for 
wound contraction 
and 
reepithelialization 
No intervention for 
closure is 
advocated 
Otherwise termed 
as the delayed 
primary closure 
wherein the wound 
is intervened by 
debridement and 
formal closure 
(suturing/grafts). 
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PHASES OF WOUND HEALING: 
According to the current model, the methodology of wound healing is 
subdivided into an early phase characterized by hemostasis and cellular 
propagation and a cellular phase that involves a wide array of mechanisms which 
all together mounts an inflammatory reaction and helps to strengthen the epithelial 
layer. 
INFLAMMATORY PHASE: 
                          INITIATION OF INJURY                2-4 DAYS 
The exposed collagen initiates the clotting cascade. The initial hemostatic 
effect is brought by the vasoconstrictors, thromboxane A2 and prostaglandin 2-
alpha which is then supported by the vasodilatory effect of histamine.  Platelet-
derived growth factor (PDGF) and transforming growth factor beta (TGF-b) 
attracts the neutrophils which removes the bacteria and macrophages which is a 
primary element in wound healing which extends its effects in the consequent 
phase of wound healing.  
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PROLIFERATIVE PHASE: 
The primary cell in this phase which begins by day 3 is the fibroblast which 
shows a spike on day 7 from the injury. Type III collagen is mainly produced 
which aids in angiogenesis, epithelialization either from the basement membrane 
or the wound edges depending on the presence/absence of the basement 
membrane. Wounds that heal by secondary intention are mainly dependent on the 
granulation tissue produced in this phase. 
 
 
Cells involved in wound healing. The order of  appearance of cells in a 
wound are depicted in sequence from left to right, and the color bars 
represent the range of days of  each cell type in the wound. 
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REMODELLING PHASE: 
Fibroblasts differentiates into myofibroblasts which helps in the contraction 
of the wound. This along with the reorganization of collagen provides 80% of the 
tissue strength. 
[10]
 The type I collagen replaces the type III collagen and the 
vascularity of the wound decreases. This process continues for about 6 months to 1 
year from the time of injury. Excess of type III collagen along with multiple factors 
promotes the keloid and hypertrophic scar formation. 
 
FACTORS INFLUENCING THE WOUND HEALING: 
LOCOREGIONAL FACTORS: 
 A moist wound environment promotes wound healing. 
 Edema  
 Ischemia 
 Necrosis 
 Presence of foreign bodies 
 Tissue perfusion 
 Decreased oxygen tension 
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SYSTEMIC FACTORS: 
 Increasing age 
 Smoking and alcohol 
 Nutritional deficiency 
 Inflammation of the surrounding skin 
 Immunosuppression  
 Connective tissue and metabolic disorders 
 
WOUND CONTRACTION 
DEFINITION: 
It denotes the healing of the wound in a centripetal way. 
As the skin in most parts of the body is adhered to the subcutaneous tissue, 
wound contraction is less evident in humans except in certain areas lie the back of 
the neck and the buttocks. 
The wound contracts at a rate of about 0.6-0.75mm/day beginning on the 3
rd
 
or the 4
th
 day following an injury and stops beyond the 16
th
 day. 
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No single theory in the mechanism of wound contraction is proved 
satisfactory even though many theories like the pull theory, push theory and the 
picture frame theory have been proposed. 
EPITHELIZATION: 
A mechanism of wound healing taking place at the level of the surface of the 
body is termed epithelization and depends on multiple factors like the site and size 
of the wound, status of the blood supply and the pathological changes in the 
wound. It is a very good example of healing of the wound by regeneration in which 
the lost epithelial cells are replaced by the epithelial component alone. It begins in 
the first 24 hrs following an injury and takes place on dermal wounds, wounds on 
the surface of the tracheobronchial tree, gut, urinary bladder and the uterus. 
STAGES OF EPITHELIZATION: 
 Detachment and the motility of the basal cells from the dermal component to 
the region of the defect in the cell. 
 Proliferation of cells and reconstruction of the normal cellular function. 
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GRANULATION TISSUE: 
A highly vascular tissue consisting of proliferating fibroblasts, endothelial 
cells, macrophages and pleuripotent pericytes nested in a matrix composed of 
fibronectin and hyaluronic acid is denoted to as the granulation tissue.                    
ROLE OF THE GRANULATION TISSUE: 
Acts as a cornerstone for the proliferating epithelial cells over which the 
epidermis which is regenerating can migrate and helps in the formation of the scar 
tissue. Structural particles, proteases, chemotactic and growth factors 
[11]
 are the 
important elements that help in the formation of the granulation tissue. 
COLLAGEN: 
Collagen produced by the fibroblasts are abundant in the connective tissues. 
The deposition of collagen takes place through a series of process which includes 
the biosynthesis of tropo-collagen, formation of fibril element, the maturation and 
degradation of collagen. 
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DIABETIC FOOT ULCER (DFU) 
Diabetic foot ulcers which are the precursor to lower extremity amputations 
are chronic wounds with peripheral sensory neuropathy as the primary factor and 
micro or macro-angiopathy and changes due to sepsis as the other factors. Foot 
ulceration is a pivotal event in the diabetic patients and has a major impact on the 
mortality, morbidity and quality of patients‟ lives.  
CLASSIFICATION OF DIABETES MELLITUS 
TYPE 1 DIABETES Absolute insulin deficiency 
IDDM (Insulin-Dependent Diabetes Mellitus) 
TYPE 2 DIABETES Insulin resistant or insulin deficient 
NIDDM (NonInsulin-Dependent Diabetes Mellitus) 
OTHER TYPES Genetic defects of β cell function or insulin action 
Endocrinopathies 
Drugs or chemicals 
Infections 
Gestational diabetes 
 
The aetiopathogenesis of foot changes in diabetic foot ulcers was described 
by Oakley and Dupless. 
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RISK FACTORS FOR ULCERATION: 
[12] 
GENERAL FACTORS: 
 Uncontrolled hyperglycaemia. 
 Peripheral vascular disease. 
 Duration of diabetes. 
 Chronic renal disease. 
 Blindness or visual loss. 
 Old age. 
 Reduced host immunity.  
 
LOCAL FACTORS:  
 Structural foot deformity – arch collapse. 
 Callus formation.  
 Peripheral neuropathy. 
 Trauma. 
 Improper footwear. 
 History of prior ulceration or amputation. 
 Prolonged pressure – increase in weight bearing due to obesity. 
 Altered blood viscosity. 
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 Glycosylation of sin proteins. 
 Micro – circulatory abnormality. 
 Restricted joint mobility. 
 
MECHANISM OF INJURY 
 Protracted low pressure over a bony prominence which produces ulcers over 
the medial, lateral and dorsal aspects of the foot. It occurs in association with 
the ill-fitting shoes. 
 Prolonged and repetitive stress which results in the ulcer on the sole of the 
foot. 
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CHARACTERISTIC FEATURES OF DFU BASED ON AETIOLOGY 
Feature Neuropathic Ischaemic Neuroischaemic 
Sensation Sensory loss to 
touch, vibration, 
pressure and pain. 
Painful Degree of sensory 
loss 
Callus/necrosis Callus present in 
the weight bearing 
areas and thick 
Necrosis or distal 
eschar is present. 
Minimal callus 
formation. 
Wound bed Pink and 
granulating. 
Pale and covered 
with slough with 
poor granulation. 
Poor granulation. 
Foot temperature 
and pulses 
Warm with 
bounding pulses. 
Dilated and 
prominent veins. 
Cool with absent pulses. 
Skin colour Normal or red. Pale/bluish in colour 
Skin condition Dry skin with 
fissures due to 
decreased 
sweating. 
Delay in healing 
due to thin and 
fragile skin. 
High risk of 
infection. 
Ankle reflexes Absent Present  
Typical location Metatarsal heads, 
heel and dorsum of 
clawed toes. 
Plantar aspect 
(80%) 
Tips of toes, nail 
edges, margins of 
the foot. 
Margins of the foot 
and toes. 
Prevalence 55% 10% 35% 
Foot deformities Clawed toes, 
Charcot 
deformities. 
Absent 
toes/forefoot 
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DIABETIC FOOT INFECTIONS 
These are usually polymicrobial in nature and are the most frequent 
complication in diabetic individuals comprising of 70% of the patients followed by 
the foot ulcers. 
RISK FACTOR FOR INFECTION: 
 History of walking barefoot 
 A positive probe-to-bone test  
 Diabetic foot ulcer present for more than 30 days  
 History of recurrent foot ulcers  
 Traumatic wound 
 Previous lower extremity amputation 
 The presence of peripheral arterial disease in the affected limb  
 Loss of protective sensation  
 The presence of renal insufficiency 
RISK FACTORS FOR CHARCOT’S FOOT: [4]                               
 Presence of peripheral sensory neuropathy 
 History of prior trauma or amputation 
 Foot deformities. 
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 Joint infections.  
                      
 
DIABETIC NEUROPATHY 
 
It incorporates a wide array of abnormalities which affects the proximal or 
the distal peripheral nerves and the autonomic nervous system. The most common 
is the distal neuropathy. 
Hyperglycaemia exerts oxidative stress on nerve cells and causes 
glycosylation of nerve cell proteins and thus acts as a base in the pathophysiology 
of diabetic foot ulcers. Other biochemical derangements include an increase in the 
production of advanced glycosylated end products and defect in the polyol 
pathway. 
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SENSORY NEUROPATHY: 
Patients are unaware of the regional trauma to the foot due to the loss of pain 
perception, which produces callus formation with tissue necrosis beneath the 
callus. This leads to the formation of cavities that erupts onto the skin surface 
resulting in ulcer formation. The other sensory components include paraesthesia, 
loss of joint sense, Glove and stocking anaesthesia and Charcot‟s joints. There is a 
delay in the patient seeking medical help due to the absence of symptoms. 
 
MOTOR NEUROPATHY: 
The motor component includes wasting and weakness of the intrinsic foot 
muscles which causes an imbalance of the foot flexors and extensors, ligaments, an 
abnormal collagen metabolism and multiple joint subluxations which produces 
anatomic deformities in the foot, abnormal gait and subsequent formation of ulcers. 
 
AUTONOMIC NEUROPATHY: 
The affected autonomic nerves impede the function of the sweat gland 
producing the breakdown in the skin and the formation of fissures in the epidermis. 
Due to this, the skin loses its ability to moisturize evident as epidermal cracks. 
26 
 
 
 
CHANGES EVIDENT IN THE VASCULAR SYSTEM: 
Uncontrolled hyperglycaemia causes endothelial cell dysfunction, ischemia 
and foot ulcers due to an increase in the levels of plasma thromboxane A2. 
Immune changes in diabetic foot ulcers demonstrate an Increase in the 
apoptosis of T lymphocytes which eventually reduces the healing response. 
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DIABETIC VASCULOPATHY: 
[13] 
 The risk of developing peripheral arterial disease is high in the diabetic 
individuals which eventually leads to the formation of critical limb ischaemia. 
MACROANGIOPATHY: 
 Diabetics with uncontrolled hyperglycaemia in association with other 
comorbid conditions like hypertension, hyperlipidaemia and smoking hastens the 
atherosclerotic changes in the distal vessels mainly which is evident in the form of 
thickening, narrowing or occluding of the vessels. 
 The most common finding in the diabetic individuals is the calcification 
which is more evident in the media of the vessel and this condition is termed the 
„MONCKEBERG SCLEROSIS‟. The vessels turn out to be rigid in case of 
calcification and gives a false impression of elevated perfusion pressure. The 
popliteal artery is the vital artery. 
CHANGES MANIFESTATED DUE TO ISCHAEMIA: 
 Claudication pain 
 Formation of ulcers. 
 Cold limb with absent pulses which may lead to formation of gangrene. 
 Brittle nails. 
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 Delay in wound healing. 
MICROANGIOPATHY: 
 Microvascular involvement due to the impedence of the capillaries 
contributes to the formation of diabetic foot ulcers. the capillaries are blocked by 
the RBCs which are rigid and flat in case of diabetics. 
 Small vessels like the arterioles and the capillaries which are the site of 
involvement of the microangiopathy are blocked leading to the formation of patchy 
areas of gangrene. The changes are evident in the form of basement membrane 
thickening which is demonstrated by staining with Periodic Acid Schiff (PAS). 
PATHOGENESIS OF INFECTION: 
      The „Hypoxic‟ environment along with the dysfunction in the metabolism and 
impaired host defences makes it liable for the entry of the micro-organisms. 
Impairment of the autonomic nerves which causes fissures/ cracks on the skin are 
the portal of entry of the organisms. Hyperglycaemia which impedes the adhering 
capacity of the granulocytes, diapedesis,chemotaxis and phagocytosis in 
association with the immunosuppression progresses to infection which causes 
ischaemia and gangrene. The infection spreads to the underlying soft tissues and 
results in osteomyelitis which initially is suppurative and progresses to necrosis, 
sequestrum formation and chronic osteomyelitis. 
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 Gram positive, aerobic cocci like the Staphylococcus aureus and beta 
hemolytic Streptococci are the most frequently isolated organisms. Antimicrobial 
therapy is initiated empirically and then revised depending on the reports from the 
culture and sensitivity. 
AMPUTATION: 
 The incidence of lower extremity amputation is 4 to 7 times higher in the 
diabetic men and women when compared to the non-diabetic individuals. 
RISK FACTORS FOR AMPUTATION: 
 Peripheral arterial disease. 
 History of prior foot ulcers, infections or amputation. 
 Structural foot deformity. 
 Charcot foot. 
 Trauma. 
 Old age and male sex. 
 Impaired vision. 
 High in the blacks and Hispanics. 
 Poor control of the blood sugar. 
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FACTORS FAVOURING THE CHRONICITY OF THE WOUND: 
[14] 
 Nutritional deficiency – deficiency in the proteins, vitamins and the 
minerals. 
 Tissue hypoxia. 
 Infection. 
 Chronic renal insufficiency. 
 Malignancy. 
 Mechanical factors due to the pressure, repetitive injury. 
 Inadequate debridement. 
 Old age. 
 Prior radiation therapy. 
 Toxic wound care products. 
The healing in the ulcer is impeded if the hemoglobin is less than 8 gm% and 
serum albumin is less than 3 gm%. 
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ASSESSMENT OF THE DIABETIC FOOT ULCERS 
[15] 
HISTORY: 
Thorough medical, foot and the diabetic history.  One should enquire about 
the type of footwear used, any exposure to chemicals, any deformities of the foot 
or any prior history of foot infections or surgery. 
 
EXAMINATION OF THE LOWER LIMB: 
DERMATOLOGIC EXAMINATION: 
 Look for cracks/ fissure in the skin and the texture of the skin. 
 Look for lesions in between the digits, presence/absence of hair, appearance 
of the nail. 
DERMATOLOGIC MARKERS FOR DIABETES: 
 Shin spots 
 Necrobiosis lipoidica diabeticorum 
 Bullosum diabeticorum 
 Granuloma annulare 
 Acanthosis nigricans 
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EXAMINATION OF THE MUSCULOSKELETAL SYSTEM: 
Look for any structural and biomechanical deformities, gait, muscle wasting, 
contractures, prior amputation and measure the plantar pressure. 
Radiological investigation is carried out. 
EXAMINATION OF THE PERIPHERAL VASCULATURE: 
Inspect for any colour changes in the limb. The peripheral pulses should be 
palpated individually and edema has to be looked in. 
Duplex examination of both the arterial and venous system is mandatory. Measure 
the transcutaneous oxygen saturation, hallux blood pressure and ankle-brachial 
pressure index. 
NEUROLOGIC EXAMINATION: 
Assess whether he/she is able to perceive vibration sense with the aid of the 
biothesiometer, light pressure and touch, temperature and also note whether he/she 
is able to discriminate between 2 points placed apart. 
Inspect the deep tendon reflexes.  
The Semmes-Weinstein monofilament which is made to buckle so that maximum 
pressure is exerted on the testing site is the most common screening tool to check 
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for neuropathy. Applied at 10 sites and an absence in the protective threshold is 
considered when the patient is not able to perceive in atleast 7 out of the 10 sites 
tested. This monofilament should be given a recovery period of atleast 24 hours 
before applying on more than ten patients. Standard 128Hz tuning fork is also used 
to assess neuropathy. 
PLACES FOR TESTING: 
 Plantar surface of the heads of the metatarsal (minimum of 3 metatarsal 
heads) 
 The medial and lateral sides of the plantar aspect of the midfoot 
 The great toe/first toe 
 The plantar area of the heel 
 The dorsal aspect of the midfoot 
Special tests include the clonus test, Babinski and Romberg test. 
EXAMINATION OF THE ULCER: 
Position, size and depth of the wound is recorded. Assess the status of the ulcer bed 
in the form of presence/absence of granulation tissue, slough and the status of the 
wound edge. Look for signs of infection in the periwound area. Examine the ulcer 
for any exudate, necrosis and sinus tracts. 
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Clinical photographs of the ulcer at the start of the treatment and in successive 
progression is essential to determine the response to the treatment. 
EXAMINATION OF THE FOOTWEAR: 
 Type of shoe 
 Pattern and fit of footwear 
 Presence of foreign bodies 
 Orthoses. 
 
INVESTIGATIONS 
BLOOD INVESTIGATIONS: 
Routine blood examination including the complete blood count, renal and liver 
function, fasting blood sugar values, C-reactive protein, alkaline phosphatase and 
HbA1c. 
In order to rule out the other etiology, VDRL and rheumatoid factor are also 
carried out. 
URINANALYSIS: 
Examine the urine for sugar and ketone bodies. 
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WOUND CULTURE & SENSITIVITY: 
Wound swab is taken and treated based on the sensitivity of the organism. 
BIOPSY: 
Wedge biopsy to rule out malignancy from the ulcer edge which contains the 
dividing cells. Due to the presence of necrosis in the central aspect of the ulcer, 
biopsy is not taken from the centre. 
IMAGING STUDIES: 
X-RAY: 
Radiological workup of the foot – look for bony deformities, foreign bodies, 
presence of gas in the soft tissues, osteopenia, demineralization, osteomyelitic 
changes, pathological fractures and arterial calcification. 
DUPLEX: 
Duplex scan to assess the exact anatomic location of the pathology in the arteris.  
Pulse wave spectral analysis to determine the degree of stenosis. 
MR IMAGING: 
MRA is accurate for the complete evaluation of the lower limb arterial disease. 
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ARTERIOGRAPHY: 
Prior to any vascular bypass surgery, arteriography is performed. 
SCINTIGRAPHY: 
Tc-99m-MDP (Methylene DiPhosphonate) aids in the three phase bone scan and 
helps to differentiate between infections in the soft tissues and osteomyelitis. 
Increased uptake of the radiotracer is evident in case of osteomyelitis, neuropathic 
arthropathy, fractures and arthritis. 
             In order to improvise the efficacy of the bone scan in detecting infections, 
white blood cells are labeled with Tc-99 hexamethylpropyleneamineoxime (Tc-99 
HMPAO), gallium-67 citrate and indium-111 oxime (specific for acute infections). 
The EMED –SF system was employed for detecting the probable sites of ulcer by 
localizing the areas with maximum pressure. 
PET SCAN: 
Positron Emission Tomography scanning is accurate in distinguishing neuropathic 
arthropathy and osteomyelitis. 
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VASCULAR WORKUP: 
ABPI (Ankle Brachial Pressure Index): 
The pressure in the ankle is falsely elevated when the affected arteries are 
noncompressed and in the presence of medial arterial calcinosis. 
TRANSCUTANEOUS OXIMETRY: 
Transcutaneous Oxygen Tension of around 55 mmHg is considered normal.  
TcPO2 < 40 mmHg Tissue hypoxia 
TcPO2 < 30 mmHg Critical limb ischaemia 
TcPO2 > 40 mmHg After revascularization, it indicates 
healing. 
 
Toe blood pressure is effective in predicting the risk of ulceration along with the 
response to the treatment in terms of wound healing. 
INDICATIONS FOR THE VASCULAR IMAGING: 
Ankle brachial pressue index (ABPI) of less than 0.7. 
Toe blood pressure of less than 30 mmHg. 
Transcutaneous Oxygen Tension of less than 30 mmHg. 
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INTEGRATED CARE APPROACH 
An interprofessional team approach which has an access to the following 
specialists: 
 Diabetic podiatrist 
 Diabetic nurse 
 Diabetologist 
 Surgeon (general/plastic/vascular and orthopedic) 
 Dermatologist 
 Dietitian 
 Endocrinologist 
 General practitioner 
 Interventional radiologist 
 Orthotist 
 Physical and occupational therapist 
 Neurologist 
 Psychologist 
Foot ulcer, a primary integral/element of diabetes make up around 15% of 
which 12-24% require amputation. In the United States, the primary etiology of 
non-traumatic lower limb amputation is diabetes which is often preceded by a foot 
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infection of which 5% of the diabetic population develop foot ulcers and 1% may 
go in for amputation. 
Treatment of diabetic foot ulcers: 
[16] 
Check for the vascularity. If inadequate, circulation, refer to vascular 
assistant and consider angioplasty, bypass or amputation. 
INFECTION: 
SUPERFICIAL/LOCAL: 
 Debride the devitalized tissue, instill topical antimicrobial treatment along 
with the systemic antibiotic therapy. 
 Provide pressure relief. 
 Optimizing metabolic control. 
DEEP: 
Requires systemic antibiotic therapy to cover the Gram-positive, Gram-negative 
and anaerobic organisms as most of the infections are polymicrobial and later on 
culture directed antibiotics are started. 
Surgical debridement, drainage of infection with the pressure relief and strict 
glycaemic control 
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Topical antimicrobial therapy can also be added to hasten the healing. 
 
GOALS OF SURGERY IN NEUROPATHIC FOOT: 
 Reduce the risk of ulceration and amputation. 
 Reduce the foot deformity. 
 Reduce pain. 
 Providing a stable platform for ambulation. 
 Improve the appearance of the foot. 
 
PRESSURE OFFLOADING: 
The Total Contact Cast (TCC) is the gold standard which minimizes 
pressure in the at-risk areas and redistributes it evenly has certain disadvantages 
which includes: 
 Low availability and high cost. 
 Disturbs sleep and the ability of the person to carry out his/her activities. 
 Further ulceration if applied inappropriately and irritation of the skin. 
 The need for its application by trained practioners. 
41 
 
 Signs of spread of infection goes unnoticed as it does not help in daily 
inspection of the wound. 
 Contraindicated in ischaemic and neuro-ischaemic ulcers wherein the 
Scotchcast boots or the healing sandals are used. 
 
ALTERNATIVES TO TCC: 
 Foot casts. 
 Removable walking brace with rocker bottom sole. 
 Half or wedge shoes. 
 Shoe cutouts incorporated in the medial, lateral and dorsal pressure points 
and the toe box. 
 Crutches and wheelchair. 
 Patella tendon-bearing braces. 
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CLASSIFICATION SYSTEM FOR DIABETIC FOOT ULCERS 
Diabetic foot ulcers are classified based on various classification system. 
The Wagner‟s classification system is most commonly used as it determines the 
ulcer depth, presence of gangrene and loss of perfusion. 
WAGNER’S GRADING/CLASSIFICATION OF ULCER [17] 
 
UNIVERSITY OF TEXAS CLASSIFICATION 
 
Assesses the depth of ulcer, presence of infection and presence of signs of 
lower-extremity ischaemia. 
 
 
GRADE DESCRIPTION 
0 Preulcerative lesion/healed ulcer. 
1 Superficial ulcer. 
2 Ulcer deeper to subcutaneous tissue exposing soft tissues or 
bone. 
3 Deep ulcer with abscess, osteomyelitis or joint sepsis. 
4 Local gangrene – forefoot or heel. 
5 Gangrene of entire foot 
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Stage Grade 
0 I II III 
A Pre- or post- 
ulcerative 
lesions 
completely 
epithelized 
Superficial 
wound 
Wound 
infiltrating the 
tendon or 
capsule 
Wound 
peneterating to 
the bone or 
joint 
B infected Infected Infected infected 
C ischemic Ischemic Ischemic ischemic 
D Infected and 
ischemic 
Infected and 
ischemic 
Infected and 
ischemic 
Infected and 
ischemic 
 
PEDIS CLASSIFICATION 
 
 Grade Score 
 1 2 3 4 
Perfusion Normal Non-
critical 
PAD 
Critical limb 
ischaemia 
 0 
Extent/size 
(cm
2
) 
Skin 
intact 
<1cm
2 
1-3cm
2 
>3cm
2 
1 
Depth of 
tissue loss 
Skin 
intact 
Superficial Fascia, muscle 
and tendon 
Bone 
or joint 
2 
Infection None Surface Abscess,fasciitis, 
septic arthritis 
SIRS 3 
Sensation No loss Loss of 
sensation 
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SINBAD CLASSIFICATION 
 
     Assesses the Site of ulcer, Ischaemic changes, Neuropathy, Bacterial infection 
and Depth of ulcer. 
RISK CATEGORIZATION SYSTEM 
RISK 
CATEGORY 
PROTECTIVE 
SENSATION 
FOOT 
DEFORMITY 
HISTORY 
OF 
ULCER 
CONTROL 
EXAMINATION 
0 Yes No No Annual  
1 No No No Every 6 months 
2 No Yes No Every 3 months 
3 No No/yes Yes Every 1-2 months 
 
WOUND DEBRIDEMENT 
Steel and co – workers [18] described the importance of debridement which is 
nothing but the removal of devitalized tissue or any foreign matter from the ulcer 
bed in order to cut down the number of microbes and other elements that impede 
the wound healing. 
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Preparation of the ulcer bed by debridement and drainage of the exudate or 
pus is mandatory before applying any dressing. 
 
TECHNIQUE OF DEBRIDEMENT: 
Depends on various factors which includes: 
 Size and location of the ulcer. 
 Levels of exudate in the ulcer and the probable risk of infection. 
 Availability of resources. 
 Cost of the procedure. 
SURGICAL OR SHARP DEBRIDEMENT: 
This type of debridement hastens the removal of devitalized tissue. It 
produces pain which is overcome by the topical application of local anaesthetics 
and bleeding which is controlled by pressure or a hemostatic dressing like calcium 
alginate. 
AUTOLYTIC DEBRIDEMENT: 
This mode of debridement takes place in all wounds wherein the endogenous 
proteolytic enzymes like elastase, collagenase, myeloperoxidase, acid hydrolase 
from the neutrophils liquefies and breaks down the dead tissue. They aid in 
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rehydrating the ulcer bed. 
[19]
 They may hasten the wound healing process if used 
in combination with the occlusive dressings which helps in absorbing the excess 
exudate. 
MECHANICAL DEBRIDEMENT: 
A non – selective form of debridement wherein the slough and necrotic tissue 
are removed mechanically by the following methods: 
 Wet-to-dry gauze dressings.  
 Whirlpool therapy wherein pressurized irrigation of the ulcer bed is done. 
 Ultrasound method  
 Vacuum assisted closure wherein the ulcer bed is exposed to a pressure of 
approximately 125mmHg below the baseline pressure. This method provides 
a moist environment to the ulcer bed, reduces the edema, promotes the blood 
flow and helps in the formation of granulation tissue. 
It is the most rapid method. The major disadvantage is the removal of the healthy 
granulation tissue along with the dead, necrotic tissue. 
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ENZYMATIC DEBRIDEMENT: 
Naturally occurring exogenous proteolytic enzymes like collagenase, 
papain/urea and fibrinolysin/DNAse are used in combination with the endogenous 
enzymes in this mode of debridement.  
COLLAGENASE – BASED 
DEBRIDEMENT
 
PAPAIN – BASED DEBRIDEMENT 
Derived from Clostridium histiolyticum 
it aids in the digestion of the triple 
helical collagen and removal of dead 
tissue with minimal pain and blood loss. 
Extracted from Carica papaya and in the 
presence of cysteine and urea which 
reveals the papain activators and 
denatures proteins to be digested by 
papain, it helps in the breakdown of 
fibrinous material. An anti – agglutinin, 
chlorophyllin, is added to diminish the 
pain. 
 
BIOSURGICAL DEBRIDEMENT: 
Popularized in 1931, this method employs sterile maggots especially the 
green bottle fly (Lucilia sericata) which removes the necrotic tissue in a day or two 
by ingesting and killing bacteria and helps in wound healing by promoting tissue 
oxygenation.  It derives its nutrients from the digested necrotic tissue, a method 
ascribed as „extracorporeal digestion‟. If the larval therapy is incorporated for a 
prolonged duration, the healthy tissues are also damaged. 
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CHEMICAL DEBRIDEMENT: 
Hydrogen peroxide and hypochlorite are instilled for a short duration to 
remove the slough from the ulcer bed. 
 
DRESSING USED IN DIABETIC FOOT ULCERS 
Wound dressings covering the aspects of wound healing are an integral part 
in the management of diabetic foot ulcers. One should be cautious in adopting a 
dressing for a foot ulcer as it depends on the ulcer characteristics, cost and the 
patient concern. Any dressing adopted should be changed often and the wound 
should be inspected. 
Moist wound environment as evident from the work of Winter, 
[20]
 Hinman 
and Maibach has to be provided to address multiple factors that will help in wound 
healing by controlling infection allowing exchange of gases. There may be 
considerable effects on the outcome and no particular dressing is available to suit 
all scenarios due to the shortfalls in the research – based evidence. 
Factors to be noted while choosing a dressing includes: location, extent of 
the wound, amount and type of exudate, status of the surrounding skin, 
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effectiveness of the other therapies, risk of infection, comfort and quality of life of 
the patient. 
 
 
CHARACTERISTICS OF AN IDEAL DRESSING: 
 Create a moist environment for the wound which promotes wound healing. 
 Promotes gaseous exchange and thermal insulation. 
 Non – toxic and hypoallergenic. 
 Helps in frequent changing and inspection of the wound. 
 Limit the oedema of the tissues. 
 Helps in absorbing the exudate and is impermeable to micro – organisms. 
 Less adherence with the wound surface and removed with minimal pain. 
 
NONADHERENT OR LOW-ADHERENCE DRESSINGS: 
Once regarded as the treatment for diabetic foot ulcers are now being used as 
the control arm in clinical studies conducted on the newer form of dressings. They 
are simple, atraumatic, inexpensive, hypoallergenic and well tolerated and provides 
a moist environment due to minimal absorbency. 
 
They are used in low to high 
exuding wounds. 
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INTERACTIVE DRESSINGS: 
Can be left in place for long duration with minimal disruption in the wound 
surface and decreased risk of contamination. They aid in the debridement of 
necrotic tissues and promotes the growth of granulation tissue  and  helps in re – 
epithelialization. 
HYDROCOLLOID DRESSINGS: 
The first ever interactive dressing to be introduced using hydrocolloid 
materials which are occlusive, acts as an absorbent layer on a film or foam and 
semipermeable to vapor was the second preferred choice of dressing NEXT TO 
nonadherent dressing as it helps in the autolysis of necrotic tissue. They were 
introduced for the preservation of fruits. The major disadvantages are unpleasant 
odour, overgranulation and maceration. Sodium carboxy methyl cellulose acts as 
an adhesive agent in this type of dressing. 
       Controversies exist regarding their use in the management of infected wounds 
but some evidence suggests its use in infected wounds as it controls infection by 
increasing the infiltration of polymorphonuclear leukocytes.
 
HYDROGEL DRESSINGS: 
         Hydrogel dressings identical to hydrocolloid dressings in their mechanism to 
facilitate autolysis of necrotic tissue differ in the fact that they increase the 
moisture content extensively in dry wounds due to the presence of hydrophilic sites 
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leading to maceration of the necrotic tissues. These dressings are not ideal in 
wounds where anaerobic infection is suspected. 
Available as the flexible sheet form or the amorphous form.They have to be used 
as an adjunct to sharp debridement of necrotic eschar. The have to be implemented 
with utmost care in limb ischaemic patients since the dry gangrene may rapidly 
progress to wet gangrene. 
FOAM BASED DRESSINGS: 
       Foam-based dressings introduced in the 1980s with a great capacity of 
absorbency provides thermal insulation and can be used in high exuding wounds. 
They have good absorbency rates. As these dressings adhere to the wound, 
occasional dermatitis have been noted. Do not use in dry, necrotic wounds. 
ALGINATE DRESSINGS: 
They atraumatic dressings are used in cavity wounds as they are highly 
absorbent, provide hemostasis. They contain naturally occurring polysaccharides. 
The major disadvantage of this dressing is that they may require wetting before 
removal because products like sorbsan which are highly rich in mannuric acid form 
soft hydrophilic gels. They have bacteriostatic properties. As dressing with calcium 
alginate inhibits the growth of Staphylococcus aureus in vitro and shows no 
increase in growth of other organisms like Pseudomonas, Streptococcus pyogenes, 
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or Bacteroides fragilis, they are safe to use on infected foot ulcers. Dressings needs 
to be changes on a regular basis. 
All dressing packed into the wound cavity has to be removed as retained 
dressing may cause further infection. 
IODINE PREPARATIONS: 
Iodine-based preparations are used in locally infected wounds in adjunct 
with systemic antibiotics even though there is no evidence of its beneficial effects. 
With a maximum bactericidal activity of 0.1%-1%, Povidone-iodine is used as a 
skin antiseptic. They have moderate absorbent effects. 
Iodophore based dressing also termed the slow release antiseptics is 
available in 2 preparations:  cadexomer-iodine which is ideal for dressing the 
wound cavities as they are highly absorbent and prevents skin excoriation and 
povidone-iodine which is applied for superficial ulcers. In order to prevent 
maceration of the surrounding skin, dressings have to be changed frequently and 
inspected in case of heavily exudating ulcers. to reduce infection, iodine based 
dressings are used in adjunct with silver based dressings. Some patients are allergic 
to iodine based preparations which mainly contains elemental iodine that is 
insoluble in water and absorbed systemically and hence avoided in case of thyroid 
disease or pregnancy. Wound discolouration is another major disadvantage. 
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SILVER-IMPREGNATED DRESSINGS: 
These dressings have complex antimicrobial actions which includes 
alteration in cell membrane, inhibition of bacterial cell respiration and inactivation 
of intracellular enzymes. Silver nitrate is effective against Pseudomonas 
aeruginosa. 
Silver-coated dressings that incorporates elemental silver have high 
bactericidal properties than silver nitrate which has cytotoxic effects only on host 
cells and often used in the treatment of hypergranulating tissue and silver 
sulfadiazine which is used in burns and chronic wounds. Silver sulfadiazine is well 
tolerated than silver nitrate. Discontinue the dressing if the wound shows no 
improvement in 2 weeks and wound discolouration is another disadvantage. 
They are used in low to high exuding wounds and used in adjunct with foam 
or alginate based dressings. 
 
HYPERBARIC OXYGEN THERAPY:   
This method exerts toxic effect on the anaerobes, upgrades the activity of 
aminoglycosides, vancomycins, promotes angiogenesis and proliferation of the 
fibroblasts and aids in collagen formation. 
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PHENYTOIN:  
When administered topically, it stimulates the proliferation of the fibroblasts 
and the formation of the granulation tissue by inhibiting the effect of collagenase. 
 
SKIN SUBSTITUTES/ BIOENGINEERING: 
Introduced in 1987, it has been assorted into three groups namely the 
temporary, semipermanent and the permanent groups. The first ever tissue – 
engineered skin substitute popularized in 1998 showed an advancement in the 
healing of wounds due to diabetes, arterial insufficiency and venous stasis. 
They are also categorized based on their structure as either dermal or 
epidermal substitutes and composite substitutes consisting of both the dermal and 
the epidermal elements. 
 
GROWTH FACTORS: 
[21] 
 
Since its advent in the early 1980s, a wide array of growth factors has been 
advocated to regulate the migration, division and proliferation of the cells, protein 
expression, synthesis of extracellular matrix and the production of enzymes.  
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COMPARISON OF THE DIFFERENT GROWTH FACTORS 
 
 
 
 
S NO TYPE OF 
GROWTH FACTOR 
CELL OF 
ORIGIN 
ACTION CLINICAL 
TRIALS 
1 EPIDERMAL 
GROWTH FACTOR 
(EGF) 
[22] 
Platelets, 
macrophages, 
salivary glands 
and 
keratinocytes. 
Acts as a mitogen 
for the fibroblasts 
and keratinocytes. 
Venous and 
diabetic 
ulcers. 
2 TRANSFORMING 
GROWTH FACTOR 
– α (TGF-α) 
Platelets, 
activated 
macrophages, 
T-lymphocytes 
and 
keratinocytes. 
Promotes 
expression of the 
antimicrobial 
peptides. 
Venous and 
pressure 
ulcers. 
3 PLATELET 
DERIVED GROWTH 
FACTOR (PDGF) 
Platelets, 
macrophages, 
endothelial and 
smooth muscle 
cells, 
keratinocytes. 
Acts as a 
chemotactic agent 
for macrophages, 
granulocytes, 
fibroblasts and 
smooth muscle 
cells. Helps in the 
remodeling of 
wounds. 
Diabetic 
and 
pressure 
ulcers 
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4 TRANSFORMING 
GROWTH FACTOR – 
β (TGF-β) 
Platelets, 
macrophages, 
endothelial and 
smooth muscle 
cells, 
fibroblasts and 
T=lymphocytes. 
TGF-β1 and TGF-
β2: Aids in 
angiogenesis, 
propagates collagen 
production and 
inhibits degradation 
TGF-β3 (antagonist 
to TGF-β1 and β2): 
Noted in increased 
levels in fetal tissues 
and has helps in 
scarless healing in 
adults 
 
Venous 
and 
pressure 
ulcers. 
5 VASCULAR 
ENDOTHELIAL 
GROWTH FACTOR 
(VEGF) 
Endothelial 
cells 
Increases the 
vascular 
permeability. 
Diabetic 
ulcer 
6 HEPATOCYTE 
GROWTH FACTOR 
(HGF) 
Mesenchymal 
cells 
Promotes the 
proliferation of the 
epithelial and 
endothelial cells. 
 
7 FIBROBLAST 
GROWTH FACTOR 
(FGF – 1 & 2) 
Macrophages, 
mast cells, T-
lymphocytes, 
endothelial 
cells. 
Promotes 
proliferation of the 
fibroblasts and helps 
in angiogenesis, 
wound contraction 
and collagen 
deposition. 
Pressure, 
diabetic 
and 
venous 
ulcers. 
8 KERATINOCYTE 
GROWTH FACTOR 
(KGF) 
Fibroblasts Upregulates the 
migration, 
proliferation and 
differentiation of 
keratinocytes. 
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9 GRANULOCYTE 
MACROPHAGE – 
COLONY 
STIMULATING 
FACTOR (GM-CSF) 
Macrophages, 
fibroblasts and 
endothelial 
cells. 
Stimulates the 
proliferation of 
granulocytes and 
macrophages. 
Venous 
and 
arterial 
ulcers. 
10 HUMAN GROWTH 
HORMONE 
Pituitary gland Insulin growth 
factor – 1 
production 
Venous 
ulcers. 
 
 
RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR 
A small polypeptide originated from the recombinant deoxyribonucleic acid 
(DNA) technology, technology with a molecular weight of 6045 Daltons and 53 
amino acid residues and three intramolecular disulfide bonds has attracted 
researchers since its invention and proven effective in various levels of health care 
in humans.
 [23]  
It was noted in the submaxillary glands of mice and in the human 
urine. Originally, human epidermal growth factor was known as urogastrone. 
[24] 
EGF has mitogenic effects on the epithelial, endothelial, and mesothelial 
cells and has the following effects: hastens re-epithelialization, boosts the 
proliferation and tensile strength, and upgrades the long term effects on wound 
healing. 
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MECHANISM OF ACTION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phosphate which helps in the communication of the signal is denoted as „P‟. Epidermal growth 
factor (EGF) binds with EGFR. Phosphate activates MAPK pathway which enters the cell 
nucleus leading to DNA transcription and is finally expressed as protein. 
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Epidermal growth factor receptor (EGFR) situated on the cell surface has an 
intrinsic protein tyrosine kinase cytoplasmic domain, a transmembrane domain, 
and an extracellular domain which when bounded by the EGF leads to 
dimerization and autophosphorylation of the EGFR which in turn activates the 
microtubule-associated protein kinase (MAPK) pathway which is currently known 
as the "mitogen-activated protein kinase" (MAPK). 
[25]
 The transcription factors are 
phosphorylated and signal transduction is activated leading to a wide array of 
biochemical changes which includes an increase in the intracellular calcium due to 
the protein kinase C activation, protein synthesis and increased glycolysis that 
finally heads towards DNA synthesis and cellular propagation.  
EFFECTS OF EGF: 
 Acts as a mitogen for the epithelial cells, endothelial cells and the 
macrophages. 
 Helps in epithelialization. 
 Promotes angiogenesis. 
 Upregulates the secretion of collagen . 
 Stimulates the proliferation of fibroblasts. 
 Aids in scarless repair of the wounds. 
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 Encourages the rate of formation of the granulation tissue and enhances the 
healing of wounds. 
Phase II and phase III clinical studies to prove the efficacy of rhEGF has 
shown adequate wound contraction determined by the size of the wound and 
complete closure by a wide array of mechanisms. A multicenteric, phase III, 
double-blind trial has approved the use of rhEGF in diabetic foot ulcers, donor site 
skin grafts and first and second degree burns.
 
 
EUSOL DRESSING 
EUSOL (Edinburgh University Solution of lime) which contains 0.25% of 
active chlorine is available in the composition of 1.25 gms of calcium hypochlorite 
(bleaching powder) and 1.25 gms of boric acid diluted in distilled water to upto 
100mL.  
Bleaching powder is a white powder of calcium hydroxide, calcium chloride 
and calcium hypochlorite. 
 It is an antiseptic solution commonly utilized in the surgical units. 
[26] 
The pH of the solution  ranges from 7.5-8.5.  
Introduced by Lorrain Smith in the 1990s. 
[27] 
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It is used as a desloughing agent which promotes wound healing and is most 
effective against Pseudomonas organism.  
 
APPLICATIONS OF EUSOL: 
 Management of wound due to burns. 
 Surgical Dressing  In treating Ulcer. 
MECHANISM OF ACTION: 
It releases nascent chlorine within 24 hours and acts as a desloughing agent. It is 
recommended for diabetic and ischemic ulcers. In dilute concentrations, it kills the 
fibroblasts, neutrophils and endothelial cells. 
When applied to open wounds, it delays the healing. This delay is due to the 
hindrance in the formation of hydroxyproline. 
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METHODS AND MATERIALS 
STUDY GROUP        : Patients admitted in Govt Kilpauk Medical College & 
                                       Hospital.                                                              
STUDY DESIGN       : Randomized controlled trial. 
                                       Patients allocated into two groups, group I – dressing using 
                                       rhEGF (study group n=30) and II – dressing using EUSOL  
                                      (Edinburgh University Solution Of Lime)  (control group,  
                                       n=30) based on block randomization. 
SAMPLE SIZE          :  
                                       n2 = rn1 with 95% confidence interval, 80% power     
                                      35% difference in healing rate between two groups as  
                                      Clinically significant when the healing in EUSOL                
                                      (Edinburgh University Solution Of Lime) (control group)                    
                                       is 15%.            
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SAMPLE SIZE                   : 60 (30 in each group) 
PLACE OF STUDY           : Govt Kilpauk Medical College & Hospital 
DURATION OF STUDY   : 5 months 
FOLLOW UP PERIOD     : 1 month. 
METHODOLOGY: 
 60 eligible patients are chosen. 
 Clinical assessment done at time of inclusion in the study. 
 Detailed history and examination done. 
 Basic routine investigations will be done for all patients 
 Consent will be obtained for inclusion under study  
 Dressings will be changed daily. 
 All cases will be followed up for one month. 
INCLUSION CRITERIA: 
Patients admitted with diabetic foot wounds below the knee during the study period. 
 Age 20-80 years. 
 Ulcer area <5sq cm. 
 Ulcers of Wagners grade II. 
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 Patients giving consent for topical recombinant human epidermal growth factor.  
EXCLUSION CRITERIA:  
 Patients with age <20 or >80 years. 
 Patients with wounds resulting from venous insufficiency/ 
malignancy/ischaemia. 
 Patients using steroids, immune suppressive drugs, chemotherapy. 
 Patients with comorbid illness – cardiovascular, respiratory, 
immunological, hepatic, neurological illness. 
 Patients with evidence of osteomyelitis, septicaemia. 
 Ulcers of Wagners grade III, IV, V. 
 Wound sites other than lower limb. 
 Doppler showing atherosclerotic changes and venous abnormalities like 
varicosities. 
DATA COLLECTION: 
The data of each patient will be collected on a proforma specially designed 
for this study and which includes demographic details, clinical features, past 
medical history, clinical examination and laboratory values which will be analysed 
for statistical significance and correlation. 
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OBSERVATION AND RESULTS 
The present study was conducted on patients with diabetic foot ulcer 
admitted during the study period in Govt. Kilpauk Medical College and Hospital, 
Chennai.  With the help of a predesigned proforma, 60 patients were randomized 
into either the study group or the control group using an open label randomization 
technique. The student „t‟ test was used to interprete the results obtained from the 
study and the control groups. 
 
STUDY GROUP (A) – 30 patients received topical recombinant human epidermal 
growth factor (rhEGF) dressing after thorough debridement and wound wash.  
 
CONTROL GROUP (B) – 30 patients received EUSOL (Edinburgh University 
Solution Of Lime) dressing. 
The dressings were changed every morning and the ulcer was inspected for 
granulation tissue, presence/absence of exudate and slough. 
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TABLE 1 – Age wise distribution of the patients is as mentioned below. 
In the present study, diabetic foot ulcer was most common in the age group 
between 61-70 years.   
Age Distribution 
  rhEGF EUSOL 
Age (Years) No of Cases rhEGF No of Cases EUSOL 
20-30 Years 1 3% 0 0% 
31-40 Years 3 10% 3 10% 
41-50 Years 7 23% 1 3% 
51-60 Years 7 23% 8 27% 
61-70 Years 11 37% 12 40% 
71-80 Years 1 3% 6 20% 
 
GRAPH 1 – AGE WISE DISTRIBUTION 
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TABLE 2 – The sex wise distribution is as illustrated below. 
Sex Distribution 
  rhEGF EUSOL 
Sex No of Cases rhEGF No of Cases EUSOL 
Male (M) 27 90% 22 73% 
Female (F) 3 10% 8 27% 
 
In our study, diabetic foot ulcers were more common among males. 
GRAPH 2 – SEX DISTRIBUTION 
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TABLE 3 – Distribution based on the site of the ulcer. 
Site of Ulcer 
Site No of Cases Percentage 
Plantar 44 73% 
Dorsum 16 27% 
 
In our study, most of the ulcers were situated on the plantar aspect (73%) when 
compared to the dorsal aspect (27%). 
 
GRAPH 3 – DISTRIBUTION BASED ON THE SITE OF THE ULCER 
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TABLE 4 – Distribution based on the duration of diabetes among the study 
and control groups. 
Duration of Diabetes 
  rhEGF EUSOL 
Age (Years) 
No of 
Cases 
rhEGF 
No of 
Cases 
EUSOL 
0-5 Years 24 80% 12 40% 
6-10 Years 4 13% 8 27% 
10-15 Years 2 7% 6 20% 
16-20 Years 0 0% 1 3% 
21-25 Years 0 0% 2 7% 
26-30 Years 0 0% 1 3% 
 
GRAPH 4 – DISTRIBUTION BASED ON THE DURATION OF DIABETES 
                  
70 
 
The patients selected in the study were suffering from diabetes for a duration 
varying from months to years. 24 (80%) patients in Group A were suffering from 
diabetes for a duration of less than 5 years as compared to 12 (40%) patients in 
Group B. 
A total of 10 patients (33%) from Group A and 22 patients (73%) in Group B had 
surrounding cellulitis on admission. By the end of this study, one patient from 
Group A and 5 patients from Group B showed a surrounding cellulitis. 
 
TABLE 5 – distribution of the formation of granulation tissue 
Formation of Granulation Tissue 
Granulation Tissue Formation rhEGF EUSOL 
7th day 37% 5% 
14th day 52% 17% 
21st day 66% 30% 
28th day 72% 42% 
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GRAPH 5 – distribution of formation of granulation tissue on days 7, 14, 21 
and 28. 
        
 
On the 7
th
 day of treatment, patients in the study group had a mean granulation 
tissue of 37% over the wound as compared to 5% in the control group who 
received the EUSOL dressing. 
On day 14, 3 patients in the study group showed complete healing with a mean of 
52% in the formation of granulation tissue while the patients in the control group 
showed 17% mean in the formation of granulation tissue. 
On day 21, out of the remaining 27 patients in the study group who received 
rhEGF, 5 patients showed complete healing and 2 patients underwent treatment for 
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skin closure in the form of secondary suturing. A 66% mean in the formation of 
granulation tissue was noted in the rhEGF group as compared to 30% in the group 
of patients who received EUSOL dressing. 1 patient showed complete healing in 
the control group. 
By the 28
th
 day of the start of the treatment, 10 patients in the study group showed 
complete healing as compared to 1 in the control group. 3 patients in the control 
group underwent secondary suturing. The study group had a mean granulation 
tissue formation of about 72% as compared to 42% in the control group and there 
is a significant difference between the two groups with a P value of <0.0001 which 
is considered statistically significant.  
Granulation 
Tissue 
Formation 
Type of 
Dressing 
Total No 
of 
Patients 
MEAN 
Standard 
Deviation 
Standard 
Error of 
Mean 
Significance 
7th day 
rhEGF 30 37.00 26.47 4.83 
P=0.000<0.0001 
EUSOL 30 5.23 11.44 2.09 
14th day 
rhEGF 30 51.65 29.18 5.33 
P=0.000<0.0001 
EUSOL 30 16.58 15.96 2.91 
21th day 
rhEGF 25 65.60 28.26 5.65 
P=0.000<0.0001 
EUSOL 30 29.60 18.87 3.45 
28th day 
rhEGF 20 72.45 27.76 6.21 
P=0.000<0.0001 
EUSOL 26 41.54  18.60 3.65 
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The table shown below illustrates the size of the ulcer as measured on admission 
and 14
th
 day of treatment. 
TABLE 6 – size of the ulcer as estimated on admission and day 14 of 
treatment 
Size of Ulcer 
(sq.cm) 
Type of 
Dressing 
Total 
No of 
Patients 
MEAN 
Standard 
Deviation 
Standard 
Error of 
Mean 
ON 
ADMISSION 
rhEGF 30 3.85 0.79 0.14 
EUSOL 30 3.92 0.84 0.15 
14th day 
rhEGF 30 1.96 1.26 0.23 
EUSOL 30 3.31 0.96 0.17 
 
The mean size of the ulcer on admission was 3.85 sq.cm. in the study group and 
3.92 sq.cm. in the control group which gradually reduced to 1.96 sq.cm. 
In the study group and 3.31 sq.cm. in the control group as estimated on the 14
th
 day 
of treatment. There is a definite reduction in the size of the ulcer in the study group 
which received topical recombinant human epidermal growth factor. 
TABLE 7 – final outcome of the study and control group 
Final Outcome 
Final Outcome rhEGF EUSOL 
Secondary Healing (SH) 50% 43% 
Completely Healed (CH) 33% 3% 
Secondary Suturing (SS) 10% 13% 
Not Healed (NH) 7% 40% 
Total 100% 100% 
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10 patients (33%) in the study group showed complete healing as compared to 1 
(3%) in the control group. Healing by secondary intention was evident in 50% of 
the patients in the study group as compared to 43% in the control group. Ulcers 
were not healed in 2 patients (7%) in the group which received dressing with 
rhEGF as compared to 12 patients (40%) in the control group. 
GRAPH 6 – final outcome in the study and control group 
             
The patients were followed up and they had a good recovery along with the other 
modalities of management like strict glycaemic control, proper footwear etc. 
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DISCUSSION 
Foot ulcers due to diabetes are chronic in nature with prolonged inflammatory 
phase of wound healing which is evident as a delay in the wound healing. The type 
of dressings practiced in the recent times aim to promote wound healing with 
minimal trauma and reduced contamination. This study is a randomized control 
trial which compares the efficacy of topical recombinant human epidermal growth 
factor (rhEGF) with the EUSOL dressing in the healing of diabetic wounds. 
The study conducted by Doerler et al., demonstrated that the novel EGF-containing 
wound dressing was generally well tolerated and safe.              
The efficacy of EGF is reduced in the presence of neuropathy, vasculopathy, 
increasing wound severity and poor glycemic control.  
The therapeutic efficacy of topical recombinant human EGF (rhEGF) has been 
studied by Brown and colleagues, in a study of nine patients, five of whom had 
diabetes. Brown also carried out a large trial of EGF efficacy on 12 non-diabetic 
patients with chronic wounds, again with successful results. 
The mean age group is between 61-70 years in the present study. National Hospital 
Discharge Survey (NHDS) which is the second national data source documented 
more male patients suffering from diabetic foot which is the same as in our study. 
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Edmonds et al demonstrated more ulcers on the plantar aspect which is the same as 
in our study. 44 patients (73%) had ulcers on the plantar aspect of the foot. 
The rate of formation of the granulation tissue was high in the study group as 
estimated on the 7
th
, 14
th
, 21
st
 and 28
th
 day of treatment. 10 patients (33%) showed 
complete healing in the study group whereas only 1 patient (3%) showed complete 
healing in the control group. The study group had a mean granulation tissue 
formation of about 72% as compared to 42% in the control group and there is a 
significant difference between the two groups with a P value of <0.0001 which is 
considered statistically significant. 
This significant difference in Recombinant Human Epidermal Growth Factor 
Group as compared to the EUSOL group is true and has not occurred by chance.   
The results obtained demonstrate a positive contribution of topical application of 
epidermal growth factor in stimulating the process of wound healing. This method 
could have a significant impact on wound care. However, further research studies 
are needed to support and to assess the real benefits of our findings in wide 
population.  
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CONCLUSION 
Our study demonstrated the efficacy of topical recombinant human epidermal 
growth factor (rhEGF) in the healing of diabetic wounds in terms of rate of 
formation of granulation tissue and wound healing when compared with the control 
group who received EUSOL (Edinburgh University Solution Of Lime) dressing. 
Treatment with topical rhEGF can be added to the wide spectrum of treatment 
modalities available for the management of the diabetic foot ulcers after further 
research with a large population.  
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APPENDIX 
I) PROFORMA 
1. Patient name:  
2. Age: 
3. Sex: 
4. IP No:  
5. D.O.A: 
6. D.O.S: 
7. D.O.D: 
8. Department:  
9. Hospital: 
10. Occupation 
 
11. Chief complaints: 
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- ULCER/WOUND – location, number, duration, discharge from the 
ulcer, painful/painless, tingling/numbness/loss of sensation, 
discolouration. 
- PAIN – claudication/rest. 
- TRAUMA 
12. Past history: 
- DIABETES – is the patient on treatment – regular/irregular 
- Insulin/OHA, frequency of monitoring of blood glucose.  
13. Body mass index: 
14. General examination: 
15. Vitals: 
- Blood pressure b. Pulse rate c. Temperature 
16. Local examination: 
- ULCER - Site, size, number of ulcer. Depth, floor, margin and 
discharge from the ulcer. Edema, cellulitis, wasting, gangrene, 
callosity. 
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- Peripheral pulses – dorsalis pedis, anterior and posterior tibial, 
popliteal. 
17. Abdominal examination: 
18. Cardiovascular examination: 
19. Respiratory examination: 
20. Central nervous system examination: 
21. INVESTIGATIONS: 
- Complete hemogram 
- Blood group 
- Random blood sugar on admission into the hospital 
- Urine sugar/ ketone bodies 
- Renal function test 
- x-ray of the affected limb to rule out osteomyelitis 
- Doppler ultrasound of the arterial system 
- Ankle brachial pressure index 
- Culture from the pus/ slough from the ulcer 
22. TREATMENT AND ANTIDIABETICS: OHA/Insulin 
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23. FOLLOW UP NOTES: 
- size of the ulcer –discharge from ulcer –granulation tissue formation  
24. LINE OF MANAGEMENT: 
25. SURGERY: 
- Secondary suturing 
26. CONDITION OF THE PATIENT: 
27. FOLLOW UP AFTER 1 WEEK OF DISCHARGE: 
28. SIGNATURE: 
CHARACTERISTICS EUSOL (Edinburgh 
University Solution Of 
Lime) 
 
Number (%) 
TOPICAL 
RECOMBINANT 
HUMAN EPIDERMAL 
GROWTH FACTOR 
(rhEGF) DRESSING 
Number (%) 
SECONDARY 
HEALING 
  
SECONDARY 
SUTURING 
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II) MASTER CHART 
S 
NO 
AGE 
(Years) 
SEX IP NO 
DURATION 
 OF 
DIABETES 
(Years) 
SITE  
OF 
ULCER 
GRADE  
OF 
ULCER 
SIZE OF 
ULCER 
(sq.cm)  
ON 
ADMISSION 
SIZE 
OF 
ULCER 
(sq.cm) 
14TH 
DAY 
TYPE  
OF 
DRESSING 
% 
GRANULATION 
TISSUE  
7TH DAY 
% 
GRANULATION 
TISSUE 
 14TH DAY 
% 
GRANULATION 
TISSUE 
21ST DAY 
% 
GRANULATION 
TISSUE  
28TH DAY 
FINAL  
OUTCOME 
1 63 M 13160 6 P 2 4 2 rhEGF 38  50  70  90  SH 
2 52 M 13483 3 P 2 4.8 3.8 rhEGF 15  21  55  78  SH 
3 65 M 13533 2 P 2 2.5 0 rhEGF 90  100      CH 
4 42 F 13962 3 P 2 3 1.2 rhEGF 55  60  75  96  SH 
5 55 M 13976 5 D 2 4 2.2 rhEGF 36  45  65  90  SH 
6 44 M 14015 1 P 2 4.8 2.6 rhEGF 33  46  70  80  SH 
7 66 M 14192 7 P 2 3 1.5 rhEGF 38  50  72  95  SH 
8 54 M 14370 5 P 2 4.8 2.3 rhEGF 40  52  65  78  SH 
9 63 M 14482 4 P 2 3 0 rhEGF 95  100      CH 
10 35 M 14673 1 D 2 4 2.9 rhEGF 20  28  40  60  SH 
11 57 M 14782 1 D 2 4 1.2 rhEGF 50  70  95  100  CH 
12 68 M 14997 3 P 2 4.8 0.9 rhEGF 65  81  100    CH 
13 46 M 15014 1 D 2 4 2.8 rhEGF 15  30      SS 
14 58 M 15209 2 P 2 2.5 0.1 rhEGF 90  96  100    CH 
15 74 F 15367 6 P 2 4.8 4.6 rhEGF 0  4  6  10  NH 
16 47 M 15382 2 P 2 4.8 2.4 rhEGF 28  50  60  72  SH 
17 68 M 15396 10 P 2 3 0 rhEGF 55  100      CH 
18 55 M 15931 4 D 2 4 3.6 rhEGF 4  10  14  20  NH 
19 62 M 16328 2 D 2 4 0.9 rhEGF 60  78  100    CH 
20 41 M 16778 1 P 2 2.5 1.2 rhEGF 38  52  78  95  SH 
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S 
NO 
AGE 
(Years) 
SEX IP NO 
DURATION 
 OF 
DIABETES 
(Years) 
SITE  
OF 
ULCER 
GRADE  
OF 
ULCER 
SIZE OF 
ULCER 
(sq.cm)  
ON 
ADMISSION 
SIZE 
OF 
ULCER 
(sq.cm) 
14TH 
DAY 
TYPE  
OF 
DRESSING 
% 
GRANULATION 
TISSUE  
7TH DAY 
% 
GRANULATION 
TISSUE 
 14TH DAY 
% 
GRANULATION 
TISSUE 
21ST DAY 
% 
GRANULATION 
TISSUE  
28TH DAY 
FINAL  
OUTCOME 
21 61 M 17282 1 D 2 4.8 3.8 rhEGF 10  21  35  52  SH 
22 38 M 17736 1 P 2 4 3.6 rhEGF 4  10  15  20  SH 
23 59 F 20742 3 P 2 3 0.3 rhEGF 75  90  100    CH 
24 49 M 21452 2 P 2 4 1 rhEGF 40  75  100    CH 
25 69 M 22382 12 D 2 3.75 2.6 rhEGF 15  31  65  88  SH 
26 29 M 23305 1 D 2 4 3.2 rhEGF 9  20      SS 
27 43 M 28837 3 P 2 3 1.4 rhEGF 34  53  75  90  SH 
28 64 M 29062 2 D 2 4.8 1.4 rhEGF 33  71  90  100  CH 
29 40 M 31452 1 P 2 3 2.8 rhEGF 0  7  25  45  SS 
30 68 M 32120 13 P 2 4.8 2.4 rhEGF 25  50  70  90  SH 
31 53 M 13120 3 P 2 4 4 EUSOL 0  0  2  8  NH 
32 62 F 13143 5 P 2 3 2.5 EUSOL 5  17  25  40  SH 
33 37 M 13540 2 P 2 4.8 3.8 EUSOL 6  21  30  50  SH 
34 70 M 13690 24 P 2 4.8 4.1 EUSOL 5  15  40  60  SH 
35 55 M 13876 10 P 2 3 2.5 EUSOL 3  17  34  50  SH 
36 68 F 13997 12 D 2 4 3.4 EUSOL 0  15  35    SS 
37 39 M 14210 3 P 2 2.5 1.8 EUSOL 1  28  45  70  SH 
38 64 M 14406 8 P 2 4.8 4 EUSOL 6  17  30    SS 
39 75 M 14667 12 P 2 4 3.4 EUSOL 5  15  20  35  NH 
40 62 M 14768 7 P 2 4.8 4 EUSOL 4  17  25  44  SS 
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S 
NO 
AGE 
(Years) 
SEX IP NO 
DURATION 
 OF 
DIABETES 
(Years) 
SITE  
OF 
ULCER 
GRADE  
OF 
ULCER 
SIZE OF 
ULCER 
(sq.cm)  
ON 
ADMISSION 
SIZE 
OF 
ULCER 
(sq.cm) 
14TH 
DAY 
TYPE  
OF 
DRESSING 
% 
GRANULATION 
TISSUE  
7TH DAY 
% 
GRANULATION 
TISSUE 
 14TH DAY 
% 
GRANULATION 
TISSUE 
21ST DAY 
% 
GRANULATION 
TISSUE  
28TH DAY 
FINAL  
OUTCOME 
41 73 F 14867 5 D 2 4 3.6 EUSOL 0  10  20  33  NH 
42 58 M 14983 8 P 2 3 2.5 EUSOL 5  17  25  46  SH 
43 66 M 15020 11 P 2 4.8 4.4 EUSOL 0  8  20  28  NH 
44 44 M 15112 2 P 2 4.8 4.8 EUSOL 0  0  2  7  NH 
45 65 M 15372 4 P 2 4 2.9 EUSOL 1  28  50  70  SH 
46 52 M 15693 7 P 2 3 2.8 EUSOL 0  7  15  30  NH 
47 68 M 15903 4 D 2 4 3.4 EUSOL 5  15  35  48  SH 
48 79 F 16339 15 P 2 2.5 0.2 EUSOL 65  92  100    CH 
49 35 M 16792 1 D 2 5 4.6 EUSOL 0  8  15  24  NH 
50 69 F 16928 5 P 2 2.5 2.1 EUSOL 4  16  34  50  SH 
51 56 M 17233 7 P 2 4 3 EUSOL 8  25  30  44  SH 
52 80 M 19809 26 P 2 4.8 3.8 EUSOL 1  21  45  72  SH 
53 70 F 20849 22 P 2 3 3 EUSOL 0  0  9  15  NH 
54 54 M 23832 4 P 2 4 3.4 EUSOL 5  15  33  50  SH 
55 57 M 25067 2 P 2 4.8 4.3 EUSOL 4  10  20  33  NH 
56 73 M 26404 15 D 2 4 3.6 EUSOL 3  10  35  48  NH 
57 63 F 29172 10 P 2 4.8 4 EUSOL 7  17  25  35  NH 
58 77 F 30586 20 D 2 3 2.2 EUSOL 10  27  63  75  SH 
59 58 M 33672 15 P 2 4.8 4.2 EUSOL 4  13  20    SS 
60 64 M 34128 9 P 2 3 3 EUSOL 0  0  6  15  NH 
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KEY WORDS USED IN MASTER CHART 
rhEGF -  Recombinant Human Epidermal Growth Factor 
EUSOL -  Edinburgh University Solution Of Line 
SH -  Secondary Healing 
CH -  Completely Healed 
NH -  Not Healed 
SS -  Secondary Suturing 
